Received by email:

File: EMH - EW News Release for Acquisition of Vanc Shares (April 2018)(01656837xB87D3).docx

Early Warning News Release 
VICTORIA, BC, April 17, 2018 - Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) ("Emerald" or the "Company"
--->) announces that it acquired today control and direction (via its 51% owned affiliate, 1160305 B.C. Ltd.) of 3,030,303
---> common share purchase warrants (the "Warrants") of Vanc Pharmaceuticals Inc. ("Vanc") of Suite 810- 789 West Pender S
--->treet, Vancouver, British Columbia, V6C 1H2 pursuant to a supply and distribution agreement (the "Transaction").  Each
---> Warrant is exercisable into one common share of Vanc (a "Share") for a period of 24 months at an exercise price of $0
--->.33, subject to accelerated expiry provisions.  

Immediately before the Transaction, the Company had direct ownership of 1,666,667 Shares representing approximately 5.
--->86% of the issued and outstanding Shares and 1,666,667 share purchase warrants for the purchase of an additional 1,666
--->,667 Shares. Following the Transaction, the Company held direct ownership of 1,666,667 Shares representing approximate
--->ly 5.86% of the issued and outstanding Shares.  The Company also holds directly and has control and direction over 4,6
--->96,970 share purchase warrants.  Assuming the exercise of all of the warrants, the Company would own directly and have
---> control and direction over a total of 6,363,637 Shares, or approximately 19.19% of Vanc's then issued and outstanding
---> share capital assuming no other Shares are issued.

Emerald acquired control and direction over the Warrants for investment purposes.  The Company may sell its securities
---> of Vanc either on the open market or through private dispositions in the future depending on market conditions, refor
--->mulation of plans and/or other relevant factors.

This news release is being issued pursuant to Part 3 of National Instrument 62-103 The Early Warning System and Relate
--->d Take-Over Bid and Insider Reporting Issues of the Canadian Securities Administrators.  A copy of the report filed by
---> Emerald in connection with the acquisition of the Warrants will be available on Vanc's SEDAR profile, and it can also
---> be obtained directly from the Company. 

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics (TSXV: EMH; OTCQX: EMHTF) is a Licensed Producer under Canada's Access to Cannabis for Med
--->ical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes. It is adding a 
--->500,000 ft2 greenhouse in Metro Vancouver to serve the anticipated legal Canadian adult-use cannabis market starting i
--->n 2018. Emerald owns 50% of a joint venture with Village Farms International, Inc. that is converting an existing 1.1 
--->million ft2 greenhouse in Delta, BC to grow cannabis. Emerald's team is highly experienced in life sciences, product d
--->evelopment and large-scale agribusiness. Emerald Health Therapeutics is part of the Emerald Health Group, which includ
--->es multiple companies focused on developing cannabis and cannabinoid products with potential wellness and medical bene
--->fits.

Please visit www.emeraldhealth.ca for more information or contact: 

Rob Hill       Ray Lagace
CFO       Investor Relations Manager
(800) 757 3536 Ext. #5    (800) 757 3536 Ext. #5
       invest@emeraldhealth.ca 
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the 
--->TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.